Bio-Raid

banner

發布時間:2019-07-09 00:00:00

 

這是描述信息
/
論文
全部分類

論文

  • 分類:科學研究
  • 發布時間:2019-05-29 00:00:00
  • 訪問量:0
概要:
概要:
詳情

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cellmalignancies.

Wang N1,2, Hu X1,2, Cao W1,2, Li C1,2, Xiao Y1,2, Cao Y1,2, Gu C3,4, Zhang S4, Chen L1,2, Cheng J1,2, Wang G1,2, Zhou X1,2, Zheng M1,2, Mao X1,2,Jiang L1,2, Wang D1,2, Wang Q1,2, Lou Y1,2, Cai H1,2, Yan D5, Zhang Y1,2, Zhang T3,4, Zhou J1,2, Huang L1,2.

 2020 Jan 2;135(1):17-27. doi: 10.1182/blood.2019000017.

 

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients.

 
  2020 Jan 23;10(1):8. doi: 10.1038/s41408-020-0274-9.
 

Entecavir Prophylaxis for Hepatitis B Virus Reactivation in Patients with CAR T-cell Therapy.

Cao W1Wei J2Wang N3Xu H4Xiao M5Huang L4Cao Y1Li C1Xiao Y1Gu C6Zhang S6Li D1Zhang Y5Zhang T7Zhou J5Huang L5.
 
 2020 Apr 14. pii: blood.2020004907. doi: 10.1182/blood.2020004907.
 
 

Efficacy and Toxicity for CD22/CD19 Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed/Refractory Aggressive B-cell Lymphoma Involving the Gastrointestinal Tract

Chen Zeng 1, Jiali Cheng 1, Tongjuan Li 1, Jin Huang 1, Chunrui Li 1, Lijun Jiang 1, Jue Wang 1, Liting Chen 1, Xia Mao 1, Li Zhu 1, Yaoyao Lou 1, Jianfeng Zhou 1, Xiaoxi Zhou 2
 
Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13
 
 

Long‐term outcomes of relapsed/refractory double‐hit lymphoma (r/r DHL) treated with CD19/22 CAR T‐cell cocktail therapy

 DOI: 10.1002/ctm2.176

                                                                                                  

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia

掃二維碼用手機看

Bio-Raid

武漢波睿達生物科技有限公司 

 

公司地址:武漢市東湖新技術開發區高新二路388號

武漢光谷國際生物醫藥企業加速器3.1期第3幢4層、

5層(1)廠房
聯系電話:027-59318269
公司郵箱:
cart@bio-raid.com

 

Bio-Raid

掃碼關注
波睿達生物公眾號

国产av一区二区三区